Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PGNY$28.42+0.70(+2.53%)New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits[9:51:41 AM ET]CAE$25.79+0.05(+0.19%)New Horizons Ahead: Applications Open November 1 for the Eighth Annual Air Canada and CAE Captain Judy Cameron Scholarship (NASDAQ: CAE) (TSX: CAE) – Air Canada and CAE are once again joining forces to support more women building careers in aviation through the Captain...[9:43:00 AM ET]AFL$121.35-0.64(-0.52%)My Special Aflac Duck® Puts Love and Care in the hands of Children at Riley Hospital Children receiving care for cancer and blood disorders at Riley Hospital for Children in Indianapolis have a new companion to help bring comfort and...[9:40:00 AM ET]GMAB$52.07+7.40(+16.57%)Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer[9:40:00 AM ET]ETD$19.97+0.05(+0.25%)Doug Bergeron Identifies Proven Retail Operator Stefanie Tsen Ward as Interim CEO Candidate for Ethan Allen[9:30:00 AM ET]FGPR$20.21+0.01(+0.05%)Ferrellgas and Operation Warm to Give More Than 350 Flagstaff Children New Winter Coats[9:30:00 AM ET]FGPR$20.21+0.01(+0.05%)Ferrellgas and Operation Warm to Give 350 Bay City Children New Winter Coats[9:30:00 AM ET]JXN$134.05-1.01(-0.75%)QVT Issues Second Report on Jackson Financial (JXN) Subsidiary Brooke Life Reinsurance Co. Underscoring Near-Term Liquidity Challenges[9:30:00 AM ET]APH$80.12+1.91(+2.44%)Industrial Growth Partners Announces Sale of AdvancedPCB Industrial Growth Partners ("IGP") is pleased to announce that it has entered into a definitive agreement to sell AdvancedPCB Holdings, LLC...[9:27:00 AM ET]BLGO$0.06-0.01(-7.25%)BioLargo Introduces barebird, a Company-Owned Brand, Reuniting Key Teams Behind Pooph's Consumer Market Success[9:25:00 AM ET]TWOSF$0.24-0.00(-0.04%)T2 Metals to Attend the 52nd Annual New Orleans Investment Conference[9:25:00 AM ET]MOB$3.36+0.07(+2.13%)Mobilicom to Showcase Cybersecure Portfolio Highlighting Newly Launched SwarmiX at ARC WEPTAC Conference[9:22:00 AM ET]COSM$0.24+0.01(+3.35%)Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target[9:20:00 AM ET]MGN$3.53+0.47(+15.36%)Megan Holdings Limited Announces Pricing of Up to $7.5 Million Follow-on Public Offering[9:20:00 AM ET]ADSE$9.55+0.25(+2.69%)ADS-TEC Energy Advances One of Europe's Largest Battery Storage Projects as Building Permit Nears[9:18:00 AM ET]

DARE · NASDAQ

Dare Bioscience, Inc.

$0.67 0.00 (+0.15%)

Company overview

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's products include XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive, and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$10M
Employees
23
Headquarters
San Diego, CA
Website
darebioscience.com
CEO
Sabrina Martucci Johnson
Listed
April 10, 2014
P/E
-0.64
Dividend yield
0.00%

Company financials

Revenue
$1.2M
Gross profit
$64,454
Operating income
-$12M
EBITDA
-$9.9M
Net income
-$12M
EPS
-$1.04
Total assets
$27.8M
Total debt
$7.2M
Gross margin
5.57%
Net margin
-1,038.77%
Earnings yield
-155.13%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

0.501.352.203.053.91
DARE 1D NASDAQ O0.64H0.68L0.64C0.67+0.03 (+3.91%)Vol18.86K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
DAREDare Bioscience, Inc. Press release Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly GlobeNewswire
DAREDare Bioscience, Inc. Press release Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer GlobeNewswire
DAREDare Bioscience, Inc. Press release Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities GlobeNewswire
DAREDare Bioscience, Inc. Stock news Contrasting RYTHM (NASDAQ:RYM) & Dare Bioscience (NASDAQ:DARE) Defense World
DAREDare Bioscience, Inc. Press release Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection GlobeNewsWire
DAREDare Bioscience, Inc. Press release Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil GlobeNewsWire
DAREDare Bioscience, Inc. Press release Daré Bioscience Announces Peer-Reviewed Publication of GlobeNewswire
DAREDare Bioscience, Inc. Press release Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand GlobeNewsWire
DAREDare Bioscience, Inc. Press release Daré Bioscience Presentation for H.C. Wainwright 28th GlobeNewswire
DAREDare Bioscience, Inc. Press release Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth GlobeNewsWire
DAREDare Bioscience, Inc. Press release Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series GlobeNewsWire
DAREDare Bioscience, Inc. Stock news Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript Seeking Alpha
DAREDare Bioscience, Inc. Press release Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society GlobeNewsWire
DAREDare Bioscience, Inc. Press release Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment GlobeNewsWire
DAREDare Bioscience, Inc. Press release DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List GlobeNewsWire
DAREDare Bioscience, Inc. Stock news Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript Seeking Alpha
DAREDare Bioscience, Inc. Stock news Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates Zacks Investment Research
DAREDare Bioscience, Inc. Press release Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances GlobeNewsWire
DAREDare Bioscience, Inc. Stock news Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript Seeking Alpha
DAREDare Bioscience, Inc. Press release Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 GlobeNewsWire
See more
FAQ

Questions about Dare Bioscience, Inc.

What does Dare Bioscience, Inc. do?
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's products include XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive, and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.
What is DARE's market cap?
Dare Bioscience, Inc. (DARE) is a listed stock with a live quote. The latest market cap on this page is $10M.
Where is Dare Bioscience, Inc. headquartered?
Dare Bioscience, Inc. is headquartered in San Diego, CA.
How do I get DARE news from the API?
Call GET /v1/news?tickers=DARE. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does DARE news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for DARE, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the DARE price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs